Biotech Values

[BiotechValues]

$BIAD The potential for this one to tutn EPS + soon is there.

Cash burn is now down to $70K/month and influx of $1M from Sysmex should be counted as either deferred revenue or current revenue. Because they actually received the cash in Q1, I'd say it will be recorded as current and with no debt, zero dilution, and cash burn of 70K/month, that will have a big impact on the fundamentals.

That's why I see it as far less risky than most nanocaps and why (I believe) DueDiligence allowed me to post about it here.

But so we're not cluttering the board here with BIAD, please check out the BIAD board for more information: Bio-AMD I-hub